120 related articles for article (PubMed ID: 35319392)
1. Daidzein and Chicory Extract Arrest the Cell Cycle
Abdel-Hamid NM; Zakaria S; Nawaya RA; Eldomany RA; El-Shishtawy MM
Recent Pat Anticancer Drug Discov; 2022; 18(2):187-199. PubMed ID: 35319392
[TBL] [Abstract][Full Text] [Related]
2. Targeting the HIF-1α/Cav-1 Pathway with a Chicory Extract/Daidzein Combination Plays a Potential Role in Retarding Hepatocellular Carcinoma.
Zakaria S; Nawaya R; Abdel-Hamid NM; Eldomany RA; El-Shishtawy MM
Curr Cancer Drug Targets; 2021; 21(10):881-896. PubMed ID: 34382525
[TBL] [Abstract][Full Text] [Related]
3. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
4. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.
Abd-Elbaset M; Mansour AM; Ahmed OM; Abo-Youssef AM
Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1611-1624. PubMed ID: 32270258
[TBL] [Abstract][Full Text] [Related]
5. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
[TBL] [Abstract][Full Text] [Related]
6. Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling.
Chen L; Wang X; Cheng H; Zhang W; Liu Y; Zeng W; Yu L; Huang C; Liu G
Biochem Biophys Res Commun; 2020 Dec; 533(4):1162-1169. PubMed ID: 33039146
[TBL] [Abstract][Full Text] [Related]
7. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
8. A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction.
Dai XY; Zeng XX; Peng F; Han YY; Lin HJ; Xu YZ; Zhou T; Xie G; Deng Y; Mao YQ; Yu LT; Yang L; Zhao YL
Cell Physiol Biochem; 2012; 29(1-2):281-90. PubMed ID: 22415097
[TBL] [Abstract][Full Text] [Related]
9. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
You N; Liu W; Wang T; Ji R; Wang X; Gong Z; Dou K; Tao K
Oncol Rep; 2012 Dec; 28(6):2091-100. PubMed ID: 22993037
[TBL] [Abstract][Full Text] [Related]
10. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
Zhu Y; Ke KB; Xia ZK; Li HJ; Su R; Dong C; Zhou FM; Wang L; Chen R; Wu SG; Zhao H; Gu P; Leung KS; Wong MH; Lu G; Zhang JY; Jiang BH; Qiu JG; Shi XN; Lin MC
Mol Med; 2021 Feb; 27(1):15. PubMed ID: 33579185
[TBL] [Abstract][Full Text] [Related]
11. Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway.
Wang J; Yang T; Chen H; Li H; Zheng S
Biochem Biophys Res Commun; 2018 Apr; 498(3):424-430. PubMed ID: 29477843
[TBL] [Abstract][Full Text] [Related]
12. The upregulation of stromal antigen 3 expression suppresses the phenotypic hallmarks of hepatocellular carcinoma through the Smad3-CDK4/CDK6-cyclin D1 and CXCR4/RhoA pathways.
Zhao M; Wang Y; Zhang Y; Li X; Mi J; Wang Q; Geng Z; Zuo L; Song X; Ge S; Zhang Z; Tang M; Li H; Wang Z; Jiang C; Su F
BMC Gastroenterol; 2022 Aug; 22(1):378. PubMed ID: 35941537
[TBL] [Abstract][Full Text] [Related]
13. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis.
Masaki T; Shiratori Y; Rengifo W; Igarashi K; Yamagata M; Kurokohchi K; Uchida N; Miyauchi Y; Yoshiji H; Watanabe S; Omata M; Kuriyama S
Hepatology; 2003 Mar; 37(3):534-43. PubMed ID: 12601350
[TBL] [Abstract][Full Text] [Related]
14. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
15. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
16. BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.
Busche S; John K; Wandrer F; Vondran FWR; Lehmann U; Wedemeyer H; Essmann F; Schulze-Osthoff K; Bantel H
Cell Death Dis; 2021 Jul; 12(8):736. PubMed ID: 34312366
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma.
Matsuda Y
World J Gastroenterol; 2008 Mar; 14(11):1734-40. PubMed ID: 18350604
[TBL] [Abstract][Full Text] [Related]
18. Bafilomycin C1 induces G0/G1 cell-cycle arrest and mitochondrial-mediated apoptosis in human hepatocellular cancer SMMC7721 cells.
Gao X; Han L; Ding N; Mu Y; Guan P; Hu C; Huang X
J Antibiot (Tokyo); 2018 Sep; 71(9):808-817. PubMed ID: 29752478
[TBL] [Abstract][Full Text] [Related]
19. Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest.
Zhao H; Zhang Y; Sun J; Zhan C; Zhao L
Oncol Res; 2016; 23(5):237-48. PubMed ID: 27098147
[TBL] [Abstract][Full Text] [Related]
20. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
